Evofem amends note agreement with Adjuvant, pushing maturity to December 2026
The fifth amendment to Evofem Biosciences' 2020 Securities Purchase Agreement resets the payoff date for convertible notes held by Adjuvant and strips out certain covenants.
SEC filing